Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in -mutated colorectal cancer
Background: KRAS is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and targeting the downstream effector mitogen-activated protein kinase kinase (MEK) via monothe...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
SAGE Publishing
2024-12-01
|
| Σειρά: | Therapeutic Advances in Medical Oncology |
| Διαθέσιμο Online: | https://doi.org/10.1177/17588359241303302 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|